Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic non-small-cell lung cancer: A secondary analysis of ESOGIA-GFPC-GECP 08-02 study.

[1]  C. Tournigand,et al.  Energy expenditure profiles and the risk of early limiting toxicity in older patients with cancer: The ELCAPA-25 prospective cohort survey. , 2022, Clinical nutrition.

[2]  G. Zalcman,et al.  Measuring Walking Speed Failed to Predict Early Death and Toxicity in Elderly Patients with Metastatic Non-Small-Cell Lung Cancer (NSCLC) Selected for Undergoing First-Line Systemic Treatment: An Observational Exploratory Study , 2022, Cancers.

[3]  S. Plumb,et al.  Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study , 2021, The Lancet.

[4]  M. Fakih,et al.  Geriatric Assessment-Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer: A Randomized Clinical Trial. , 2021, JAMA oncology.

[5]  H. Allore,et al.  Functional Disability Among Older Versus Younger Adults With Advanced Non–Small-Cell Lung Cancer , 2021, JCO oncology practice.

[6]  P. Lorigan,et al.  A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients – the ELDERS study , 2021, ESMO open.

[7]  K. Lam,et al.  The predictive value of G8 and the Cancer and aging research group chemotherapy toxicity tool in treatment-related toxicity in older Chinese patients with cancer. , 2020, Journal of geriatric oncology.

[8]  I. Miyashiro,et al.  Geriatric assessment domains to predict overall survival in older cancer patients: An analysis of functional status, comorbidities, and nutritional status as prognostic factors , 2020, Cancer medicine.

[9]  C. Tournigand,et al.  External validation of two predictive scores of chemotherapy toxicities among older patients with solid cancer, from ELCAPA prospective cohort. , 2020 .

[10]  S. Mohile,et al.  Geriatric assessment and treatment outcomes in older adults with cancer receiving immune checkpoint inhibitors. , 2020, Journal of geriatric oncology.

[11]  Y. Rolland,et al.  Low lean mass and chemotherapy toxicity risk in the elderly: the Fraction study protocol , 2019, BMC Cancer.

[12]  S. Sourdet,et al.  Impact of the comprehensive geriatric assessment on treatment decision in geriatric oncology , 2019, BMC Cancer.

[13]  Jianying Zhou,et al.  Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.

[14]  F. Barlesi,et al.  Functional status in a geriatric oncology setting: A review. , 2019, Journal of geriatric oncology.

[15]  Jimmy Ruiz,et al.  Frailty assessment predicts toxicity during first cycle chemotherapy for advanced lung cancer regardless of chronologic age. , 2019, Journal of geriatric oncology.

[16]  P. V. Van Schil,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  G. Poissonnet,et al.  Predicting early death in older adults with cancer. , 2018, European journal of cancer.

[18]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[19]  C. Chouaid,et al.  Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group. , 2017, Journal of thoracic disease.

[20]  C. Tournigand,et al.  Prognostic value of the G8 and modified-G8 screening tools for multidimensional health problems in older patients with cancer. , 2017, European journal of cancer.

[21]  C. Tournigand,et al.  Performance of Four Frailty Classifications in Older Patients With Cancer: Prospective Elderly Cancer Patients Cohort Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Daurès,et al.  Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  L. V. van Elden,et al.  Relevance of a Geriatric Assessment for Elderly Patients With Lung Cancer-A Systematic Review. , 2016, Clinical lung cancer.

[24]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[25]  I. Floriani,et al.  Estimating the risk of chemotherapy toxicity in older patients with cancer: The role of the Vulnerable Elders Survey-13 (VES-13). , 2015, Journal of geriatric oncology.

[26]  C. Gridelli,et al.  Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  D. Schrijvers,et al.  Geriatric screening results and the association with severe treatment toxicity after the first cycle of (radio)chemotherapy. , 2014, Journal of geriatric oncology.

[28]  D. McMillan.  The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. , 2013, Cancer treatment reviews.

[29]  G. Colditz,et al.  Geriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancer. , 2013, Journal of geriatric oncology.

[30]  O. Bouché,et al.  Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  B. V. van Munster,et al.  The value of geriatric assessments in predicting treatment tolerance and all-cause mortality in older patients with cancer. , 2012, The oncologist.

[32]  S. Mathoulin-Pélissier,et al.  Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  G. Lyman,et al.  Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High‐Age Patients (CRASH) score , 2012, Cancer.

[34]  A. Ravaud,et al.  Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  L. Walter,et al.  Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Supriya G Mohile,et al.  Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  M. Extermann.  Basic Assessment of the Older Cancer Patient , 2011, Current treatment options in oncology.

[38]  A. Yubero,et al.  Assessment of functional status, symptoms and comorbidity in elderly patients with advanced non-small-cell lung cancer (NSCLC) treated with gemcitabine and vinorelbine , 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[39]  B. Weber,et al.  Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  R. Pazdur,et al.  Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  R. Govindan,et al.  Differential prognostic impact of comorbidity. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  J. Wetzels,et al.  Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[43]  M. Extermann,et al.  Measurement and impact of comorbidity in older cancer patients. , 2000, Critical reviews in oncology/hematology.

[44]  J. Clément,et al.  [Development and contribution to the validation of a brief French version of the Yesavage Geriatric Depression Scale]. , 1997, L'Encephale.

[45]  Diane Podsiadlo,et al.  The Timed “Up & Go”: A Test of Basic Functional Mobility for Frail Elderly Persons , 1991, Journal of the American Geriatrics Society.

[46]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[47]  M. Lawton,et al.  Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living , 1969 .

[48]  S. Katz,et al.  STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION. , 1963, JAMA.

[49]  Y. Fujiwara,et al.  Association between the nutritional status and the severity of sarcopenia among community-dwelling elderly Japanese people. , 2016, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics.